Cargando…

Malaria Vaccines: From the Past towards the mRNA Vaccine Era

Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsoumani, Maria E., Voyiatzaki, Chrysa, Efstathiou, Antonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536368/
https://www.ncbi.nlm.nih.gov/pubmed/37766129
http://dx.doi.org/10.3390/vaccines11091452
_version_ 1785112849237934080
author Tsoumani, Maria E.
Voyiatzaki, Chrysa
Efstathiou, Antonia
author_facet Tsoumani, Maria E.
Voyiatzaki, Chrysa
Efstathiou, Antonia
author_sort Tsoumani, Maria E.
collection PubMed
description Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite life-cycle have been explored, including subunit vaccines, vectored vaccines, and whole organism vaccines with Mosquirix, a vaccine based on a recombinant protein, as the only currently approved vaccine for Plasmodium falciparum malaria. Despite the aforementioned notable progress, challenges such as antigenic diversity, limited efficacy, resistant parasites escaping protective immunity and the need for multiple doses have hindered the development of a highly efficacious malaria vaccine. The recent success of mRNA-based vaccines against SARS-CoV-2 has sparked renewed interest in mRNA vaccine platforms. The unique mRNA vaccine features, including their potential for rapid development, scalability, and flexibility in antigen design, make them a promising avenue for malaria vaccine development. This review provides an overview of the malaria vaccines’ evolution from the past towards the mRNA vaccine era and highlights their advantages in overcoming the limitations of previous malaria vaccine candidates.
format Online
Article
Text
id pubmed-10536368
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105363682023-09-29 Malaria Vaccines: From the Past towards the mRNA Vaccine Era Tsoumani, Maria E. Voyiatzaki, Chrysa Efstathiou, Antonia Vaccines (Basel) Review Plasmodium spp. is the etiological agent of malaria, a life-threatening parasitic disease transmitted by infected mosquitoes. Malaria remains a major global health challenge, particularly in endemic regions. Over the years, various vaccine candidates targeting different stages of Plasmodium parasite life-cycle have been explored, including subunit vaccines, vectored vaccines, and whole organism vaccines with Mosquirix, a vaccine based on a recombinant protein, as the only currently approved vaccine for Plasmodium falciparum malaria. Despite the aforementioned notable progress, challenges such as antigenic diversity, limited efficacy, resistant parasites escaping protective immunity and the need for multiple doses have hindered the development of a highly efficacious malaria vaccine. The recent success of mRNA-based vaccines against SARS-CoV-2 has sparked renewed interest in mRNA vaccine platforms. The unique mRNA vaccine features, including their potential for rapid development, scalability, and flexibility in antigen design, make them a promising avenue for malaria vaccine development. This review provides an overview of the malaria vaccines’ evolution from the past towards the mRNA vaccine era and highlights their advantages in overcoming the limitations of previous malaria vaccine candidates. MDPI 2023-09-04 /pmc/articles/PMC10536368/ /pubmed/37766129 http://dx.doi.org/10.3390/vaccines11091452 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Tsoumani, Maria E.
Voyiatzaki, Chrysa
Efstathiou, Antonia
Malaria Vaccines: From the Past towards the mRNA Vaccine Era
title Malaria Vaccines: From the Past towards the mRNA Vaccine Era
title_full Malaria Vaccines: From the Past towards the mRNA Vaccine Era
title_fullStr Malaria Vaccines: From the Past towards the mRNA Vaccine Era
title_full_unstemmed Malaria Vaccines: From the Past towards the mRNA Vaccine Era
title_short Malaria Vaccines: From the Past towards the mRNA Vaccine Era
title_sort malaria vaccines: from the past towards the mrna vaccine era
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536368/
https://www.ncbi.nlm.nih.gov/pubmed/37766129
http://dx.doi.org/10.3390/vaccines11091452
work_keys_str_mv AT tsoumanimariae malariavaccinesfromthepasttowardsthemrnavaccineera
AT voyiatzakichrysa malariavaccinesfromthepasttowardsthemrnavaccineera
AT efstathiouantonia malariavaccinesfromthepasttowardsthemrnavaccineera